Osteosarcoma, chondrosarcoma, and chordoma

Jeremy S. Whelan, Lara Davis

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their biologic and clinical heterogeneity, is that management guidelines are inadequate to inform the range of individual patient-treatment decisions from diagnosis, approaches to surgery, chemotherapy, radiotherapy, treatment of recurrence, palliative care, and quality of survivorship. Of high-grade sarcomas, OSs are among the most curable, with more than two-thirds of patients with localized disease likely to achieve long-term survival. Neoadjuvant chemotherapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard of care for resectable OS in those younger than 40 years. Outcomes for OS presenting with unresectable metastases or recurrent disease, or in those older than 40 years are generally poor. Overall results have improved little for all patients with OS, and new treatments are needed. Surgical resection remains the cornerstone of management for chondrosarcoma and chordoma. However, the application of new biologic insights to therapeutic development indicates that improved treatments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is inadequate. For all these uncommon diseases, patients should be offered specialist expert care delivered by experienced multidisciplinary teams in high-volume centers.

Original languageEnglish (US)
Pages (from-to)188-193
Number of pages6
JournalJournal of Clinical Oncology
Volume36
Issue number2
DOIs
StatePublished - Jan 10 2018

Fingerprint

Chordoma
Chondrosarcoma
Osteosarcoma
Sarcoma
Therapeutics
Drug Therapy
Standard of Care
Palliative Care
Methotrexate
Doxorubicin
Cisplatin
Radiotherapy
Survival Rate
Research Personnel
Guidelines
Neoplasm Metastasis
Recurrence
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Osteosarcoma, chondrosarcoma, and chordoma. / Whelan, Jeremy S.; Davis, Lara.

In: Journal of Clinical Oncology, Vol. 36, No. 2, 10.01.2018, p. 188-193.

Research output: Contribution to journalReview article

Whelan, Jeremy S. ; Davis, Lara. / Osteosarcoma, chondrosarcoma, and chordoma. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 2. pp. 188-193.
@article{f7006db802154ca5909771e0efd85290,
title = "Osteosarcoma, chondrosarcoma, and chordoma",
abstract = "Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their biologic and clinical heterogeneity, is that management guidelines are inadequate to inform the range of individual patient-treatment decisions from diagnosis, approaches to surgery, chemotherapy, radiotherapy, treatment of recurrence, palliative care, and quality of survivorship. Of high-grade sarcomas, OSs are among the most curable, with more than two-thirds of patients with localized disease likely to achieve long-term survival. Neoadjuvant chemotherapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard of care for resectable OS in those younger than 40 years. Outcomes for OS presenting with unresectable metastases or recurrent disease, or in those older than 40 years are generally poor. Overall results have improved little for all patients with OS, and new treatments are needed. Surgical resection remains the cornerstone of management for chondrosarcoma and chordoma. However, the application of new biologic insights to therapeutic development indicates that improved treatments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is inadequate. For all these uncommon diseases, patients should be offered specialist expert care delivered by experienced multidisciplinary teams in high-volume centers.",
author = "Whelan, {Jeremy S.} and Lara Davis",
year = "2018",
month = "1",
day = "10",
doi = "10.1200/JCO.2017.75.1743",
language = "English (US)",
volume = "36",
pages = "188--193",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Osteosarcoma, chondrosarcoma, and chordoma

AU - Whelan, Jeremy S.

AU - Davis, Lara

PY - 2018/1/10

Y1 - 2018/1/10

N2 - Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their biologic and clinical heterogeneity, is that management guidelines are inadequate to inform the range of individual patient-treatment decisions from diagnosis, approaches to surgery, chemotherapy, radiotherapy, treatment of recurrence, palliative care, and quality of survivorship. Of high-grade sarcomas, OSs are among the most curable, with more than two-thirds of patients with localized disease likely to achieve long-term survival. Neoadjuvant chemotherapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard of care for resectable OS in those younger than 40 years. Outcomes for OS presenting with unresectable metastases or recurrent disease, or in those older than 40 years are generally poor. Overall results have improved little for all patients with OS, and new treatments are needed. Surgical resection remains the cornerstone of management for chondrosarcoma and chordoma. However, the application of new biologic insights to therapeutic development indicates that improved treatments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is inadequate. For all these uncommon diseases, patients should be offered specialist expert care delivered by experienced multidisciplinary teams in high-volume centers.

AB - Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their biologic and clinical heterogeneity, is that management guidelines are inadequate to inform the range of individual patient-treatment decisions from diagnosis, approaches to surgery, chemotherapy, radiotherapy, treatment of recurrence, palliative care, and quality of survivorship. Of high-grade sarcomas, OSs are among the most curable, with more than two-thirds of patients with localized disease likely to achieve long-term survival. Neoadjuvant chemotherapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard of care for resectable OS in those younger than 40 years. Outcomes for OS presenting with unresectable metastases or recurrent disease, or in those older than 40 years are generally poor. Overall results have improved little for all patients with OS, and new treatments are needed. Surgical resection remains the cornerstone of management for chondrosarcoma and chordoma. However, the application of new biologic insights to therapeutic development indicates that improved treatments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is inadequate. For all these uncommon diseases, patients should be offered specialist expert care delivered by experienced multidisciplinary teams in high-volume centers.

UR - http://www.scopus.com/inward/record.url?scp=85040549202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040549202&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.75.1743

DO - 10.1200/JCO.2017.75.1743

M3 - Review article

VL - 36

SP - 188

EP - 193

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -